NO952800L - Fremgangsmåter for forhindring av progressiv vevsnekrose, reperfusjonsskade, bakteriell translokasjon og akutt lungesviktsyndrom hos voksne - Google Patents
Fremgangsmåter for forhindring av progressiv vevsnekrose, reperfusjonsskade, bakteriell translokasjon og akutt lungesviktsyndrom hos voksneInfo
- Publication number
- NO952800L NO952800L NO952800A NO952800A NO952800L NO 952800 L NO952800 L NO 952800L NO 952800 A NO952800 A NO 952800A NO 952800 A NO952800 A NO 952800A NO 952800 L NO952800 L NO 952800L
- Authority
- NO
- Norway
- Prior art keywords
- dhea
- pct
- derivatives
- bacterial translocation
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Respiratory Apparatuses And Protective Means (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Foreliggende oppfinnelse er rettet mot en fremgangsmåte for å forhindre eller redusere ischemi etter skade, som f.eks. reperfusjonsskade etter ischemi, cellulsr ødeleggelse assosiert med ischemiske episoder, som infarktasjoner eller traumatiske skader, og således forhindre eller redusere den påfølgende progressive nekrose av vev som er assosiert med ischemien. Denne effekt oppnås ved å administrere DHEA eller DHEA-derivater til en pasient så snart som mulig etter skaden. Foreliggende oppfinnelse er videre rettet mot 'fremgangsmåter for å forhindre eller redusere bakteriell translokasjon ved ARDS (adult respiratory distress syndrome) hos en pasient. Likeledes forhindres eller reduseres bakteriell translokasjon og ARDS ved å administrere DHEA eller DHEA-derivater til en pasient. Egnede derivater av DHEA er blant annet 16a-brom- DHEA, androstendiol og derivater som har sidekjeder i 4'- og/eller 7'-stillingene og som ikke ødelegger den naturlige aktivitet av DHEA, men som er i stand til å inhibere sulfotransferase for å hindre omdannelsen av DHEA til DHEA-S.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2942293A | 1993-03-09 | 1993-03-09 | |
PCT/US1994/002558 WO1994020111A1 (en) | 1993-03-09 | 1994-03-08 | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
Publications (2)
Publication Number | Publication Date |
---|---|
NO952800D0 NO952800D0 (no) | 1995-07-14 |
NO952800L true NO952800L (no) | 1995-09-14 |
Family
ID=21848945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO952800A NO952800L (no) | 1993-03-09 | 1995-07-14 | Fremgangsmåter for forhindring av progressiv vevsnekrose, reperfusjonsskade, bakteriell translokasjon og akutt lungesviktsyndrom hos voksne |
Country Status (15)
Country | Link |
---|---|
US (3) | US5532230A (no) |
EP (1) | EP0688220B1 (no) |
JP (1) | JP2858046B2 (no) |
KR (1) | KR960700728A (no) |
AT (1) | ATE283052T1 (no) |
AU (3) | AU677308B2 (no) |
CA (1) | CA2153895A1 (no) |
CZ (1) | CZ193495A3 (no) |
DE (1) | DE69434149T2 (no) |
ES (1) | ES2229215T3 (no) |
FI (1) | FI953814A (no) |
HU (1) | HUT72968A (no) |
NO (1) | NO952800L (no) |
SK (1) | SK103195A3 (no) |
WO (1) | WO1994020111A1 (no) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5641766A (en) * | 1990-08-29 | 1997-06-24 | Humanetics Corporation | UP-regulation of immune system with Δ 5-Androstenes |
US5922701A (en) * | 1992-05-01 | 1999-07-13 | University Of Utah Research Foundation | Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue |
US5929060A (en) * | 1992-05-01 | 1999-07-27 | University Of Utah Research Foundation | Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue |
US20020091155A1 (en) * | 1995-06-22 | 2002-07-11 | Btg Pharmaceutical Corp. | Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1 |
US5846963A (en) * | 1995-06-07 | 1998-12-08 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
US5587369A (en) * | 1993-03-09 | 1996-12-24 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
US5977095A (en) * | 1993-03-09 | 1999-11-02 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome |
US20020032160A1 (en) * | 1995-02-24 | 2002-03-14 | Nyce Jonathan W. | Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels |
US5660835A (en) * | 1995-02-24 | 1997-08-26 | East Carolina University | Method of treating adenosine depletion |
US5859000A (en) * | 1995-06-07 | 1999-01-12 | University Of Utah Research Foundation | Method for reducing mast cell mediated allergic reactions |
US5736537A (en) | 1995-09-12 | 1998-04-07 | Estee Lauder, Inc. | Dehydroep:androsterone sailcylate useful against skin atrophy |
US6576659B1 (en) * | 1996-12-05 | 2003-06-10 | Bio-Technology General Corp. | Use of oxandrolone in the treatment of burns an other wounds |
US6117429A (en) * | 1997-08-11 | 2000-09-12 | Weider Nutrition International, Inc | Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors |
US5958946A (en) * | 1998-01-20 | 1999-09-28 | Styczynski; Peter | Modulation of hair growth |
US6230713B1 (en) * | 1998-01-29 | 2001-05-15 | Margaret R. Dalesandro | Determining a treatment plan for patients undergoing thrombotic event by monitoring P-selectin |
AU763307B2 (en) * | 1998-02-04 | 2003-07-17 | Charlotte-Mecklenburg Hospital Authority | Androsterone derivatives for inhibiting DNA binding of AP-1 and airway smooth muscle proliferation |
WO1999052532A1 (en) * | 1998-04-14 | 1999-10-21 | Pharmadigm, Inc. | Method for reducing central nervous system impairment |
US20080015174A1 (en) * | 1998-11-24 | 2008-01-17 | Reading Christopher L | Metabolic Disease Treatments |
US20030060425A1 (en) * | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
US20060079492A1 (en) * | 1999-10-25 | 2006-04-13 | Ahlem Clarence N | Compositions and treatment methods |
US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
US6667299B1 (en) | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
PT1955700E (pt) * | 1999-09-30 | 2011-05-04 | Harbor Biosciences Inc | Tratamento terap?utico de doen?as associadas ao receptor de androg?nios |
GB2363984A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids |
GB2363983A (en) | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 7-hydroxyepiandrosterone |
EP2135611A1 (en) | 2001-03-01 | 2009-12-23 | Hollis-Eden Pharmaceuticals Inc. | Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy |
WO2002085296A2 (en) * | 2001-04-24 | 2002-10-31 | Epigenesis Pharmaceuticals, Inc. | Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent |
WO2002085297A2 (en) * | 2001-04-24 | 2002-10-31 | East Carolina University | Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease |
GB2378898A (en) * | 2001-08-14 | 2003-02-26 | Hunter Fleming Ltd | Prophylactic and therapeutic use of hydroxysteroids |
EP1553954A4 (en) * | 2002-06-17 | 2009-12-23 | Epigenesis Pharmaceuticals Llc | DIHYDRATE DEHYDROEPIANDROSTERONE AND METHOD FOR THE TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE LUNG DISEASE, COMPOSITIONS THEREOF |
US7405207B2 (en) * | 2002-06-17 | 2008-07-29 | Epigenesis Pharmaceuticals, Inc. | Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof |
WO2004019953A1 (en) * | 2002-08-28 | 2004-03-11 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment methods |
US20040121991A1 (en) * | 2002-12-20 | 2004-06-24 | Araneo Barbara A. | Dehydroepiandrosterone (DHEA) congeners for prevention and/or treatment of ulcers |
EP1615944A4 (en) * | 2003-04-01 | 2010-08-11 | Harbor Biosciences Inc | ANTI-ORANGE PROBLEMS WITH MARGINAL AGONIST EFFECT AND METHOD OF USE |
US20050026884A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
US20090274676A1 (en) * | 2003-07-31 | 2009-11-05 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
US20090285899A1 (en) * | 2003-07-31 | 2009-11-19 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease |
US20050026890A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease |
US20090263381A1 (en) * | 2003-07-31 | 2009-10-22 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease |
US20050113318A1 (en) * | 2003-07-31 | 2005-05-26 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
US20090285900A1 (en) * | 2003-07-31 | 2009-11-19 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
US20050026880A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease |
US20050101545A1 (en) * | 2003-07-31 | 2005-05-12 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
US20050026881A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease |
US20050026848A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease |
US20090297611A1 (en) * | 2003-07-31 | 2009-12-03 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
US20050085430A1 (en) * | 2003-07-31 | 2005-04-21 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
US20050026879A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
US20050026883A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
US20110209699A1 (en) * | 2003-07-31 | 2011-09-01 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
US20050026882A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |
US20050038004A1 (en) * | 2003-07-31 | 2005-02-17 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
US20050043282A1 (en) * | 2003-07-31 | 2005-02-24 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
EP2471536A1 (en) | 2004-09-29 | 2012-07-04 | Harbor BioSciences, Inc. | Steroid analogs and characterization and treatment methods |
US20070027217A1 (en) * | 2005-05-27 | 2007-02-01 | Ehrlich H Paul | Composition and Method for Preventing Secondary Burn Ischemia |
US20060281724A1 (en) * | 2005-06-08 | 2006-12-14 | Loria Roger M | Methods for Treating Shock |
US8273702B2 (en) | 2006-02-17 | 2012-09-25 | Wake Forest University Health Sciences | Wound healing compositions containing keratin biomaterials |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4898694A (en) * | 1987-11-25 | 1990-02-06 | Schwartz Arthur G | 17-Hydroxy-steroids |
US5001119A (en) * | 1987-11-25 | 1991-03-19 | Schwartz Arthur G | 16-substituted androstanes and 16-substituted androstenes |
US5175154A (en) * | 1987-11-25 | 1992-12-29 | Research Corporation Technologies, Inc. | 5 α-pregnan-20-ones and 5-pregnen-20-ones and related compounds |
US5110810A (en) * | 1991-02-08 | 1992-05-05 | Virginia Commonwealth University | Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of platelet aggregation |
US5162198A (en) * | 1991-02-08 | 1992-11-10 | Virginia Commonwealth University | Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of thrombuxane production and platelet aggregation |
US5206008A (en) * | 1991-04-15 | 1993-04-27 | Virginia Commonwealth University | Enhancement of immune response |
-
1994
- 1994-03-08 EP EP94911522A patent/EP0688220B1/en not_active Expired - Lifetime
- 1994-03-08 AU AU64007/94A patent/AU677308B2/en not_active Ceased
- 1994-03-08 HU HU9502126A patent/HUT72968A/hu unknown
- 1994-03-08 DE DE69434149T patent/DE69434149T2/de not_active Expired - Fee Related
- 1994-03-08 KR KR1019950703800A patent/KR960700728A/ko not_active Application Discontinuation
- 1994-03-08 WO PCT/US1994/002558 patent/WO1994020111A1/en active IP Right Grant
- 1994-03-08 CA CA002153895A patent/CA2153895A1/en not_active Abandoned
- 1994-03-08 JP JP6520289A patent/JP2858046B2/ja not_active Expired - Fee Related
- 1994-03-08 US US08/284,688 patent/US5532230A/en not_active Expired - Fee Related
- 1994-03-08 SK SK1031-95A patent/SK103195A3/sk unknown
- 1994-03-08 AT AT94911522T patent/ATE283052T1/de not_active IP Right Cessation
- 1994-03-08 ES ES94911522T patent/ES2229215T3/es not_active Expired - Lifetime
- 1994-03-08 CZ CZ951934A patent/CZ193495A3/cs unknown
-
1995
- 1995-05-19 US US08/446,569 patent/US5489581A/en not_active Expired - Fee Related
- 1995-05-19 US US08/446,568 patent/US5583126A/en not_active Expired - Fee Related
- 1995-07-14 NO NO952800A patent/NO952800L/no unknown
- 1995-08-11 FI FI953814A patent/FI953814A/fi unknown
-
1997
- 1997-05-08 AU AU20132/97A patent/AU691776B2/en not_active Ceased
- 1997-05-08 AU AU20131/97A patent/AU687704B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
JPH08507531A (ja) | 1996-08-13 |
ATE283052T1 (de) | 2004-12-15 |
FI953814A0 (fi) | 1995-08-11 |
AU2013297A (en) | 1997-07-10 |
DE69434149T2 (de) | 2006-07-20 |
US5489581A (en) | 1996-02-06 |
AU2013197A (en) | 1997-07-10 |
DE69434149D1 (de) | 2004-12-30 |
CA2153895A1 (en) | 1994-09-15 |
US5583126A (en) | 1996-12-10 |
AU677308B2 (en) | 1997-04-17 |
ES2229215T3 (es) | 2005-04-16 |
AU6400794A (en) | 1994-09-26 |
WO1994020111A1 (en) | 1994-09-15 |
HUT72968A (en) | 1996-06-28 |
FI953814A (fi) | 1995-11-07 |
EP0688220B1 (en) | 2004-11-24 |
US5532230A (en) | 1996-07-02 |
KR960700728A (ko) | 1996-02-24 |
AU687704B2 (en) | 1998-02-26 |
AU691776B2 (en) | 1998-05-21 |
HU9502126D0 (en) | 1995-09-28 |
EP0688220A1 (en) | 1995-12-27 |
CZ193495A3 (en) | 1996-04-17 |
SK103195A3 (en) | 1996-12-04 |
EP0688220A4 (en) | 1998-04-01 |
JP2858046B2 (ja) | 1999-02-17 |
NO952800D0 (no) | 1995-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO952800L (no) | Fremgangsmåter for forhindring av progressiv vevsnekrose, reperfusjonsskade, bakteriell translokasjon og akutt lungesviktsyndrom hos voksne | |
CZ154695A3 (en) | The use of anticonvulsive preparations when treating neurological lesions occurring in case of injury | |
ES2167608T3 (es) | Composicion basada en monoxido de nitrogeno como medicamento. | |
IL113010A0 (en) | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration | |
WO1998055074A3 (en) | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome | |
HU9603042D0 (en) | Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration | |
EP1733734A3 (en) | Placental alkaline phosphatase to control diabetes | |
GB9317636D0 (en) | Use of dexmedetomidine | |
AU1794601A (en) | Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs | |
PL322061A1 (en) | Method of reducing the size of infarcted area using cytocoline | |
IE890244L (en) | Protecting tissue from reperfusion injury | |
MEADE | The prevention of secondary tissue destruction in burns | |
Taylor | Excision of the proximal end of the femur for hip stiffness in myelomeningocele | |
Widenfalk et al. | Recurrent herpes simplex virus infections in the adult hand | |
Raj et al. | Penile Block | |
Coffman | Air bag injuries and occupant protection: Huelke DF, Moore JL, Ostrom M. J Trauma. 1992; 33: 894-98 | |
Chilton | Efficacy of adding nebulized ipratropium bromide to nebulized albuterol therapy in acute bronchiolitis: Schuh S, Johnson D, Canny G, Reisman J, Shields M, Kovesi T, Kerem E, Bentur L, Levison H, Jaffe D. Pediatrics. 1992; 90: 920–923 | |
Levinson et al. | BP and Hypertension | |
Ferni et al. | Antihypertensive activity and prevention of cardiac hypertrophy in shr after long term treatment with dramedilol | |
RM et al. | Two cases of injury to the femoral artery. | |
Alemany | Andrés Combalía, MD, PhD Orthopaedic Staff Associate Professor |